期刊
FUTURE ONCOLOGY
卷 16, 期 10, 页码 517-523出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2019-0844
关键词
Bruton tyrosine kinase; BTK inhibitor; chronic lymphocytic leukemia; clinical trials; comparative effectiveness; hematologic; leukemia; ibrutinib; zanubrutinib
类别
资金
- BeiGene Company Ltd, San Mateo, CA, USA - BeiGene
Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib - a first-in-class inhibitor of BTK. Off-target kinase inhibitions by ibrutinib are thought to contribute to its adverse events. Zanubrutinib is a next-generation BTK inhibitor with minimal off-target effects, sustained BTK occupancy in peripheral blood mononuclear cells and lymph nodes from patients with B-cell malignancies and promising responses in patients with CLL. Described here is a head-to-head Phase III study comparing the efficacy and safety of zanubrutinib with those of ibrutinib in patients with CLL/small lymphocytic lymphoma in the relapsed/refractory setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据